Tesamorelin
High EvidenceA GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy.
What It Is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is considered a more potent GHRH analog than sermorelin, with a longer duration of action. Beyond lipodystrophy, tesamorelin has gained significant research attention in 2024–2026 for liver health and cognitive function. In a randomized, double-blind, multicenter trial for non-alcoholic fatty liver disease (NAFLD/NASH) in HIV patients, tesamorelin produced a 37% relative reduction in hepatic fat fraction from baseline versus placebo and prevented progression of liver fibrosis — only 10% of treated patients saw worsening fibrosis compared to 35% on placebo. Hepatic transcriptomic analysis revealed increased expression of oxidative phosphorylation genes and decreased expression of inflammation and tissue repair gene sets, suggesting tesamorelin enhances hepatic mitochondrial function and lipid oxidation. For cognitive health, a randomized controlled trial of 1 mg daily tesamorelin for 20 weeks in healthy older adults and individuals with mild cognitive impairment showed significantly improved cognitive test scores, particularly in executive function. A new clinical trial (NCT06554717) is evaluating tesamorelin as an adjunct to exercise for metabolic health. A 2026 meta-analysis of randomized controlled trials published in ScienceDirect synthesized evidence confirming tesamorelin as an effective and targeted therapy for HIV-associated lipodystrophy — significantly reducing visceral adipose tissue (VAT), trunk fat, waist circumference, and hepatic fat while modestly increasing lean body mass. The analysis confirmed that tesamorelin preferentially targets visceral (organ-surrounding) fat without significantly reducing subcutaneous fat, limb fat, or overall body weight, establishing its unique mechanism profile among GH-related therapies. Tesamorelin's dual benefit of metabolic optimization and cognitive support has positioned it among the most researched GHRH analogs for age-related health in 2026.
Why Researchers Study It
Tesamorelin occupies a unique position as an FDA-approved GHRH analog with expanding research relevance beyond its original indication. Its ability to reduce hepatic fat and prevent fibrosis progression via enhanced mitochondrial function, combined with demonstrated cognitive benefits in older adults, makes it one of the most clinically validated peptides bridging metabolic and neurological aging research.
Proposed Mechanisms
- Stimulates pulsatile growth hormone release from the anterior pituitary via GHRH receptor activation
- Enhances hepatic mitochondrial function and lipid oxidation, reducing intrahepatic fat
- Upregulates oxidative phosphorylation gene expression while downregulating inflammatory pathways in liver tissue
- Improves insulin sensitivity and reduces visceral adiposity through GH-mediated lipolysis
- May support cognitive function through GH/IGF-1 axis signaling in the central nervous system
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (RCT) | HIV-associated lipodystrophy (Phase 3) | Significant reduction in visceral adipose tissue; FDA-approved indication | Source |
| Human (RCT) | NAFLD/NASH in HIV patients — multicenter double-blind | 37% relative reduction in hepatic fat fraction; fibrosis progression in 10% vs 35% placebo | Source |
| Human (RCT) | Healthy older adults and MCI patients — 1mg daily, 20 weeks | Significantly improved cognitive test scores, particularly executive function | Source |
| Hepatic transcriptomics | NAFLD in HIV — gene expression analysis | Increased oxidative phosphorylation gene sets; decreased inflammation and tissue repair gene expression | Source |
| Meta-analysis (2026) | HIV-associated lipodystrophy — pooled RCTs | Confirmed significant reductions in VAT, trunk fat, waist circumference, and hepatic fat; modest lean mass increase; preferential targeting of visceral fat without reducing subcutaneous or limb fat | Source |
Commonly Discussed Benefits
Safety & Cautions
- FDA-approved only for HIV-associated lipodystrophy; other uses are off-label
- May affect glucose metabolism; monitor blood sugar
- Contraindicated in active malignancy
- Requires prescription and medical supervision
- NAFLD and cognitive benefits demonstrated in clinical trials but not approved indications
Comparisons
See how Tesamorelin compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Falutz J. et al. — Effects of tesamorelin on body composition. JAMA. 2007 PubMed
- [2] Stanley TL. et al. — Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV. 2019 PubMed
- [3] Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD — JCI Insight PubMed
- [4] Baker LD. et al. — Effects of GHRH on cognitive function in adults with MCI and healthy older adults. Arch Neurol. 2012 PubMed
- [5] Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a meta-analysis of RCTs — Obesity Research & Clinical Practice. 2026 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
CJC-1295
Medium EvidenceA growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
Ipamorelin
Medium EvidenceA selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
Sermorelin
Medium EvidenceA GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment.
CJC-1295 (DAC)
Medium EvidenceA long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification.